Yes, generic Viagra is available in the U.S. The original patent for Viagra was set to expire in 2020; however, Pfizer entered into an agreement to allow Teva Pharmaceuticals to launch the generic. In 2020, other generic manufacturers will be able to enter the market with generic Viagra. Pfizer is also offering its own generic that ditches the blue color (it’s white) and half of the $65-a-pill retail price.
Generic Viagra has been available in Canada since 2012. In Europe, Viagra became available generically in 2013.
The lower dose form of Revatio (sildenafil) became available generically in the U.S. in November 2012 because it is used for a different condition (pulmonary arterial hypertension). In the U.S., doctors may legally prescribed generic Revatio “off-label” to patients preferring a lower priced form of Viagra for ED; however, multiple tablets may be needed as the dose form of Revatio only comes in a 20 milligram (mg) tablet. However, doctors are under no obligation to prescribe Revatio off-label.
The recommended dose of Viagra is 50 mg, as needed, approximately 1 hour before sexual activity. Doses may vary between 25 and 100 mg. The dose may be adjusted based on doctor recommendations, but it should not exceed 100 mg per dose or be taken more than once per day. Prices for generic Revatio (sildenafil 20 mg) will vary, too, and discount coupons for the generic Revatio may be found online to be used at your local pharmacy.
More about Viagra
The ease of taking an oral tablet for erectile dysfunction (ED) has revolutionized ED treatment. Sildenafil is the generic formulation of Pfizer’s Viagra, the “little blue pill” that has gained immense popularity for treatment of erectile dysfunction (ED). It was originally approved in the U.S. in 1998, and over 30 million prescriptions have been dispensed for Viagra in 120 countries.
ED is a common sexual problem for men and its frequency increases with age. A large survey conducted in the United States determined about half of all men 40 to 70 years of age experience some degree of ED. Roughly 30 million men in the U.S. and over 100 million men globally suffer from ED.
Viagra (sildenafil) was the first phosphodiesterase 5 (PDE5) inhibitor approved to treat erectile dysfunction (ED). Other competitor treatments now also on the market for ED include tadalafil (Cialis) and vardenafil (Levitra). These products are expected to lose patent in 2017 or 2018, and generics for these drugs may become available at that time, even before Viagra.